期刊文献+

湖南某三甲医院人工关节置换术后深静脉血栓预防的前瞻性研究 被引量:3

Prospective study of deep vein thrombosis prophylaxis in patients with artificial joint replacement in a tertiary hospital in Hu'nan
暂未订购
导出
摘要 目的评估湖南某三甲医院骨科在人工关节置换术后深静脉血栓(deep venous thrombosis,DVT)预防的现状和预防后DVT的发生情况。方法选择2012年6月~2012年10月中南大学湘雅医院接受人工关节置换患者100例,记录入选患者人口学和病史资料、手术资料、术后DVT预防情况等。入选患者统一于术后7~10 d行双侧下肢深静脉彩超检查,术后28 d行电话随访,记录死亡和大出血事件。结果所有患者均进行了基本预防措施、物理预防措施和药物预防措施相结合的联合预防。其中35例患者术后首次口服利伐沙班时间迟于美国胸科医生协会发表的《抗栓与溶栓治疗询证指南》第8版(ACCP-8)推荐的术后10 h。采取预防措施后有2例患者彩超发现无症状性下肢DVT,未见肺栓塞病例,术后28 d随访未出现死亡和大出血事件的发生。结论该医院骨科人工关节置换术后DVT预防措施与指南符合率高,但首次给药时间应更加及时与准确。术后彩超结果显示,规范的预防措施能够降低DVT的发生率,但不能杜绝其发生。 Objective To evaluate the status of deep vein thrombosis (DVT) prophylaxis and the incidence of the DVT after prophylaxis in patients with artificial joint replacement in a tertiary hospital in Hu'nan. Methods 100 patients with artificial joint replacement in Xiangya Hospital of Central South University from June 2012 to October 2012 were enrolled, the demographic data and medical history, surgical materials, and DVT prophylaxis status were recorded. All patients were examined by color Doppler ultrasound 7-10 days postoperatively, and a follow-up of death and massive bleeding were performed on the 28th day after the operation. Results The combination prophylaxis was applied to all the patients, including the basic, physical and drug prophylaxis. In 35 cases out of 100, Rivaroxaban was given later than I0 h postoperatively, inconsistent with ACCP-8 recommendations (Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines). 2 patients receiving prophylaxis were diagnosed with asymptomatic DVT by color Doppler ultrasound. No pulmonary embolism was found in any case. No death report or massive bleeding was found in the postoperative follow-up. Conclusion The accordance of the DVT prophylaxis after artificial joint replacement with the ACCP-8 guidelines is high in this tertiary hospital. However, the patients should take the first dose of Rivaroxaban timely and accurately. The results of color Doppler ultrasound show that incidence of DVT can be reduced but not eliminated by the prophylaxis.
作者 杨硕 李康华
出处 《中国医药导报》 CAS 2013年第9期46-48,共3页 China Medical Herald
关键词 人工关节置换术 DVT预防 彩超 前瞻性 Artificial joint replacement DVT prophylaxis Color Doppler ultrasound Prospective
  • 相关文献

参考文献14

  • 1Geerts WH,Bergqvist D,Pineo GF,et al. Prevention of venous throm-boembolism .-American College of Chest Physicians Evidence -BasedClinical Practice Guidelines (8th Edition) [J]. Chest,2008,133 (6Supp 1):38IS-453S.
  • 2中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志,2009,29(6):602-604. 被引量:534
  • 3Eriksson BI,Borris LC, Dahl OE,et al. Dose-escalation study of ri-varoxaban (BAY 59-7939) -an oral, direct Factor X a inhibitor-forthe prevention of venous thromboembolism in patients undergoing to-tal hip replacement [J]. Thromb Res,2007,120(5) :685-693.
  • 4Wells PS,Anderson DR,Rodger M,et al. Derivation of a simple clin-ical model to categorize patients probability of pulmonary embolism :increasing the models utility with the SimpliRED D -dimer [J].Thromb Haemost ,2000,83(3) :416-420.
  • 5Agnelli G,Gallus A,Goldhaber SZ,et al. Treatment of proximaldeep -vein thrombosis with the oral direct factor X a inhibitor ri-varoxaban (BAY 59-7939):the ODlXa-DVT (oral direct Factor Xainhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis)study [J]. Circulation, 2007,116(2) : 180-187.
  • 6Mueck W,Eriksson BI,Bauer KA,et al. Population pharmacokineticsand pharmacodynamics of rivaroxaban -an oral, direct factor X a in-hibitor -in patients undergoing major orthopaedic surgery [JJ.ClinPharmacokinet,2008,47(3) :203-216.
  • 7Eriksson BI,Borris LC,Friedman RJ,et al. Rivaroxaban versus enoxa-parin for thromboprophylaxis after hip arthroplasty [J], N Engl J Med,2008,358(26):2765-2775.
  • 8Agnelli G,Prandoni P,Becattini C,et al. Extended oral anticoagulanttherapy after a first episode of pulmonary embolism [J]. Ann InternMed,2003,139(l):19-25.
  • 9Fisher WD,Eriksson BI,Bauer KA,et al. Rivaroxaban for thrombo-prophylaxis after orthopaedic surgery : pooled analysis of two studies[J]. Thromb Haemost,2007,97(6) :931-917.
  • 10徐利群.彩色多普勒超声诊断小腿静脉血栓形成的研究[J].医药论坛杂志,2004,25(21):22-23. 被引量:14

二级参考文献36

  • 1邱贵兴,杨庆铭,余楠生,翁习生,王凯,李晓林.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究[J].中华骨科杂志,2006,26(12):819-822. 被引量:431
  • 2Ollendorf DA,Vera-Llonch M,Oster G.Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.Am J Health Syst Pharm,2002,59(18):1750-1754.
  • 3Geerts WH,Pineo OF,Heir JA,et al.Prevention of venous thromboembolism:the Seventh ACCP Conference on Antithromboric and Thrombolytic Therapy.Chest,2004,126 (3 Suppl):S338-400.
  • 4Mosby's Dictionary of Medicine,Nursing & Health Professions.7th ed.St.Louis,MO:Mosby,2006:115-116,335,520,1454,1849,1949.
  • 5Piovella F,Wang CJ,Lu H,et al.Deep-vein thrombosis rates after major Orthopedic surgery in Asia:an epidemiological study based on postoperative screening with centrally adjudicated bilateral venography.J Thromb Haemost,2005,3(12):2664-2670.
  • 6Heir JA,O'Fallon WM,Petterson TM,et al.Relative impact of risk factors for deep vein thrombosis and pulmonary embolism:a population-based study.Arch Intern Med,2002,162 (11):1245-1248.
  • 7Anderson FA Jr,Spencer FA.Risk factors for venous thrombcembolism.Circulation,2003,107(23 Suppl 1):9-16.
  • 8Caprini JA.Thrombosis risk assessment as a guide to quality patient care.Dis Mon,2005,51(2/3):70-78.
  • 9Geerts WH,Heit JA,Clagett GP,et al.Prevention of venous thromboembolism.Chest,2001,119(1 Suppl):S132-175.
  • 10Snow V,Qaseem A,Barry P,et al.Management of venous thromboembolism:a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.Ann Intern Med,2007,146(3):204-210.

共引文献616

同被引文献40

  • 1符东林,赵东阳,聂宇,郭标,潘檀.同期双膝关节置换治疗膝骨关节病的临床疗效[J].临床骨科杂志,2013,16(1):15-17. 被引量:13
  • 2陆再英,钟南山内科学[M].7版.北京:人民卫生出版社,2008:614.
  • 3Bozic K J,Lau E, Kurtz S,et al. Patient-related risk fac- tors for periprosthetie joint infection and postoperative mortality following total hip arthroplasty in medicare pa- tients [J]. The Journal of Bone & Joint Surgery,2012,94 (9) :794-800.
  • 4D'Apuzzo MR,Browne JA. Obstructive sleep apnea as a risk factor for postoperative complications after revision joint arthroplasty [J]. The Journal of Arthroplasty, 2012,27 (8) :95-98.
  • 5Schwarzkopf R,Thompson SL, Adwar S J, et al. Postopera- tive complication rates in the "super-obese" hip and knee arthroplasty population [J]. The Journal of Arthroplasty, 2012,27(3) :397-401.
  • 6Mustafa BO,Rathbun SW,Whitsett TL, et al. Sensitivity and specificity of uhrasonography in the diagaaosis of up- per extremity deep vein thrombosis:a systematic review [J]. Arch Intern Med,2002,162(4) :401-404.
  • 7Baumgarten M,Margolis DJ,Localio AR,et al. Extrinsic risk factors for pressure ulcers early in the hospital stay: a nested case control study [J]. J Gemntol A BiolSei Med Sci,2008,63(4) :408-413.
  • 8Jans O,Jsrgensen C, Kehlet H, et al. Role of preoperative anemia for risk of transfusion and postoperative morbidi-ty in fast - track hip and knee arthroplasty [J]. Transfu- sion,2014,54(3) :717-726.
  • 9Clark J C, Ritchie J,Song FS, et al. Complication rates, dislocation, pain, and postoperative range of motion after reverse shoulder arthroplasty in patients with and without repair of the subscapularis [J]. Journal of Shoulder and Elbow Surgery, 2012,21 ( 1 ) : 36-41.
  • 10Zmistowski B, Dizdarevie I,Jacovides CL, et al. Patients with uncontrolled components of metabolic syndrome have increased risk of complications following total joint arthroplasty [J]. The Journal of Arthroplasty, 2013,28 (6) : 904-907.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部